| DESCRIPTION | - ANGAL et al., Molecular Immunology, (19930000), vol. 30, page 105 | - |
| DESCRIPTION | - BENNET, Arch. Intern. Med., (20080000), vol. 168, pages 598 - 608 | - |
| DESCRIPTION | - GOODSON, Medical ' Applications of Controlled Release, (19840000), vol. 2, pages 115 - 138 | - |
| DESCRIPTION | - IGNATESCU et al., Thromb. Haemost, (19980000), vol. 80, pages 231 - 232 | - |
| DESCRIPTION | - LANGER, Science, (19900000), vol. 249, pages 1527 - 1533 | - |
| DESCRIPTION | - LEMON-FAVA, J Lipid Res., (20110000), vol. 52, pages 1181 - 1187 | - |
| DESCRIPTION | - LIPPI; GUIDI, Q. J. Med, (20000000), vol. 93, pages 75 - 84 | - |
| DESCRIPTION | - MARCOVINA; KOSCHINSKY, Am. J. Cardiol., (19980000), vol. 82, pages 57U - 66U | - |
| DESCRIPTION | - NEIL et al., BMJ, (20000000), vol. 321, page 148 | - |
| DESCRIPTION | - PARHOFER, Curro Pharm Des, (20110000), vol. 17, pages 871 - 876 | - |
| DESCRIPTION | - POWELL et al., "Compendium of excipients for parenteral formulations", J Pharm Sci Technol, (19980000), vol. 52, pages 238 - 311, XP009119027 | - |
| DESCRIPTION | - "Simon Broome Register Group", BMJ, (19910000), vol. 303, pages 893 - 896 | - |
| DESCRIPTION | - TAYLOR, Nucl. Acids Res., (19920000), vol. 20, pages 6287 - 6295 | - |
| DESCRIPTION | - "The Emerging Risk Factors Collaboration", 1. Am. Med. Assoc., (20090000), vol. 302, pages 412 - 423 | - |
| DESCRIPTION | - WARNICK, J. Lipid Res., (19780000), vol. 19, pages 65 - 76 | - |
| DESCRIPTION | - WU et al., J, Biol. Chem., (19870000), vol. 262, pages 4429 - 4432 | - |
| EXAMINATION | - GAUDET DANIEL ET AL, "Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)", AMERICAN JOURNAL OF CARDIOLOGY, CAHNERS PUBLISHING CO., NEWTON, MA, US, (20140618), vol. 114, no. 5, doi:10.1016/J.AMJCARD.2014.05.060, ISSN 0002-9149, pages 711 - 715, XP029045241 | |
| EXAMINATION | - Thomas Demant ET AL, "The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans", Atherosclerosis, (20010801), vol. 157, no. 2, doi:10.1016/S0021-9150(00)00732-2, ISSN 0021-9150, pages 325 - 339, XP055215912 | |
| EXAMINATION | - EVAN A. STEIN ET AL, "Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol", NEW ENGLAND JOURNAL OF MEDICINE, (20120322), vol. 366, no. 12, doi:10.1056/NEJMoa1105803, ISSN 0028-4793, pages 1108 - 1118, XP055049842 | |
| EXAMINATION | - ERIK STROES ET AL, "Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study", JOURNAL OF THE AMERICAN HEART ASSOCIATION, (20160829), vol. 5, no. 9, doi:10.1161/JAHA.116.003421, ISSN 2047-9980, pages 1 - 11, XP055656150 | |
| EXAMINATION | - D J Rader ET AL, "The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans.", Journal of Clinical Investigation, (19950301), vol. 95, no. 3, doi:10.1172/JCI117794, ISSN 0021-9738, pages 1403 - 1408, XP055215915 | |
| EXAMINATION | - Ioanna Gouni-Berthold ET AL, "Lipoprotein(a): Current Perspectives", CURRENT VASCULAR PHARMACOLOGY, NL, (20111101), vol. 9, no. 6, doi:10.2174/157016111797484071, ISSN 1570-1611, pages 682 - 692, XP055497835 | |
| OPPOSITION | - Anonymous, "Aber Lp(a) ist zu hoch, was kann man da tun?", Aktuelle Medizin, (20110526), pages 22 - 22, Aktuelle Medizin, URL: https://link.springer.com/content/pdf/10.1007/BF03368423.pdf, (20240529), XP093168119 | - |
| OPPOSITION | - Anonymous, "Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy", ClinicalTrials.gov; NCT01288443, (20110902), ClinicalTrials.gov; NCT01288443, URL: https://clinicaltrials.gov/study/NCT01288443?tab=history&a=10#version-content-panel, XP093193446 | - |
| OPPOSITION | - Anonymous, "Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality", JAMA; Emerging Risk Factors Collaboration 2009, (20090722), vol. 302, no. 4, doi:10.1001/jama.2009.1063, pages 412 - 423 | - |
| OPPOSITION | - Anonymous, "These Companies Are Racing To Develop The Next Big Cholesterol Drug", Business Insider, (20110831), pages 1 - 6, Business Insider, URL: https://www.businessinsider.com/hearty-profits-companies-racing-to-develop-the-next-big-cholesterol-drug-2011-8, (20240529), XP093168316 | - |
| OPPOSITION | - D91 - EXCERPT FROM AMGEN'S DEFENCE RE RULE 109 REQUEST | - |
| OPPOSITION | - D92 - SECOND DECLARATION OF PROF DI ANGELANTONIO_SIGNED | - |
| OPPOSITION | - D95 - "A summary of the lipid parameters measured in the anti-PCSK9 antibody clinical trials identified in HE 100 updated (BP 79.15)", ANALYSIS OF LIPID RELATED OUTCOMES MEASURED IN CLINICAL TRIALS | - |
| OPPOSITION | - Dube et al., "Lipoprotein(a) more interesting than ever after 50 years", Current Opinion in Lipidology, (20120400), vol. 23, no. 2, doi:10.1097/MOL.0b013e32835111d8, pages 133 - 140, XP055264229 | - |
| OPPOSITION | - Gary Swergold, "REGN727/SAR236553, a Fully-Human Monoclonal Antibody to Proprotein Convertase Subtilisin Kexin 9 (PCSK9), Decreases ApoB and Non-HDL-C When Administered Intravenously to Healthy Volunteer", Journal of clinical lipidology, (20110601), vol. 5, no. 3, pages 219 - 219, XP093168326 | - |
| OPPOSITION | - Mach, "ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk", European Heart Journal, (20190831), pages 1 - 78, XP055662916 | - |
| OPPOSITION | - Stein Evan A, Scott Meilis, George D. Yancopoulos, Neil Stahl, Douglas Logan, William Smith, Eleanor Lisbon, Maria Gutierrez, Cheryle Webb, Richard Wu, Yunling Du, Therese Kranz, Evelyn Gasparino, Gary D. Swergold, "Supplementary Appendix Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol", New England Journal of Medicine, (20120322), pages 1 - 53, XP093168337 | - |
| OPPOSITION | - Swergold Gary, Stephanie Biedermann, Rumiana Renard, Doug Nadler, Richard Wu, Eleanor A. Lisbon, Maria J. Gutierrez, Scott Mellis, "REGN727/SAR236553, a Fully-Human Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Monoclonal Antibody: Effects on Safety and Lipid and Lipoprotein Profiles When Administered Subcutaneously", American College of Cardiology annual scientific session & expo 2011; April 3-5, 2011, American College of Cardiology, (20110403), pages 1 - 1, XP093262425 | - |
| OPPOSITION | - Zeljko Reiner, Alberico L Catapano, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F Storey, David Wood, "ESC/EAS Guidelines for the management of dyslipidaemias", European Heart Journal, (20110101), vol. 32, pages 1769 - 11818, XP055662895 | - |
| OPPOSITION | - Anna Bennet, "Lipoprotein(a) Levels and Risk of Future Coronary Heart Disease - Large-Scale Prospective Data", JAMA internal medicine, American Medical Association, US, US , (20080324), vol. 168, no. 6, doi:10.1001/archinte.168.6.598, ISSN 2168-6106, pages 598 - 608, XP009557778 | |
| OPPOSITION | - Di Angelantonio Emanuele, Sarwar Nadeem, Perry Philip, Kaptoge Stephen, Ray Kausik K, Thompson Alexander, Wood Angela M, Lewington Sarah, Sattar Naveed, Packard Chris J, Collins Rory, Thompson Simon G, Danesh John, "Major Lipids, Apolipoproteins, and Risk of Vascular Disease", JAMA, American Medical Association, Chicago, IL, Chicago, IL, (20091111), vol. 302, no. 18, doi:10.1001/jama.2009.1619, ISSN 0098-7484, pages 1993 - 2000, XP009556379 | |
| OPPOSITION | - Kamstrup Pia R. et al. , "Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction", JAMA: Journal of the American Medical Association, American Medical Association, (20090610), vol. 301, no. 22, doi:10.1001/jama.2009.801, ISSN 0254-9077, pages 2331 - 2339, XP009557779 | |
| OPPOSITION | - Jacqueline Suk Danik , Nader Rifai, Julie E Buring, Paul M Ridker, "Lipoprotein(a), Measured With an Assay Independent of Apolipoprotein(a) Isoform Size, and Risk of Future Cardiovascular Events Among Initially Healthy Women", JAMA, (20060920), vol. 296, no. 11, doi:10.1001/jama.296.11.1363, ISSN 0098-7484, pages 1363 - 1370, XP002609986 | |
| OPPOSITION | - Davignon J; Dubuc G; Seidah N G, "The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis", Current Atherosclerosis Reports, Springer US, New York, New York, (20100901), vol. 12, no. 5, doi:10.1007/s11883-010-0123-6, ISSN 1523-3804, pages 308 - 315, XP009163743 | |
| OPPOSITION | - Knight Brian L., Perombelon Y.F.Nicholas, Soutar Anne K., Wade David P., Seed Mary, "Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects", Atherosclerosis, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (19910401), vol. 87, no. 2-3, doi:10.1016/0021-9150(91)90025-X, ISSN 0021-9150, pages 227 - 237, XP093193421 | |
| OPPOSITION | - Ghiselli, G. ; Gaddi, A. ; Barozzi, G. ; Ciarrocchi, A. ; Descovich, G., "Plasma lipoprotein(a) concentration in familial hypercholesterolemic patients without coronary artery disease", Metabolism, US, (19920801), vol. 41, no. 8, doi:10.1016/0026-0495(92)90163-5, ISSN 0026-0495, pages 833 - 838, XP023032925 | |
| OPPOSITION | - Marlys L. Koschinsky, Santica M. Marcovina, "Chapter 11 - Lipoprotein(a)", Marlys L. Koschinsky, Santica M. Marcovina, BALLANTYNE, Clinical lipidology : a companion to Braunwald's heart disease, Saunders Elsevier, (20090101), pages 130 - 143, doi:10.1016/B978-141605469-6.50015-9, ISBN 1-4160-5469-3, XP009559026 | |
| OPPOSITION | - Maya S. Safarova, Marat V. Ezhov, Olga I. Afanasieva, Yuriy G. Matchin, Ruslan V. Atanesyan, Irina Yu. Adamova, Elena A. Utkina, Gennadiy A. Konovalov, Sergei N. Pokrovsky, "Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography", Atherosclerosis Supplements, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20130101), vol. 14, no. 1, doi:10.1016/j.atherosclerosissup.2012.10.015, ISSN 1567-5688, pages 93 - 99, XP055497849 | |
| OPPOSITION | - Anuurad Erdembileg, Boffa Michael, Koschinsky Marlys, Berglund Lars, "Lipoprotein(a): A Unique Risk Factor for Cardiovascular Disease", CLINICS IN LABORATORY MEDICINE., Elsevier, US, US , (20061201), vol. 26, no. 4, doi:10.1016/j.cll.2006.07.002, ISSN 0272-2712, pages 751 - 772, XP009557782 | |
| OPPOSITION | - Marlys L. Koschinsky, Boffa Michael B., "Lipoprotein(a): An Important Cardiovascular Risk Factor and a Clinical Conundrum", ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA., W.B. SAUNDERS COMPANY, PHILADELPHIA, PHILADELPHIA , (20141201), vol. 43, no. 4, doi:10.1016/j.ecl.2014.08.002, ISSN 0889-8529, pages 949 - 962, XP055407332 | |
| OPPOSITION | - Suet N. Chen, Ballantyne Christie M., Gotto Antonio M., Tan Yanli, Willerson James T., Marian Ali J., "A Common PCSK9Haplotype, Encompassing the E670G Coding Single Nucleotide Polymorphism, Is a Novel Genetic Marker for Plasma Low-Density Lipoprotein Cholesterol Levels and Severity of Coronary Atherosclerosis /NIH Author Manuscript/", Journal of the American College of Cardiology, AMSTERDAM, NL, (20050501), vol. 45, no. 10, doi:10.1016/j.jacc.2005.01.051, ISSN 0735-1097, pages 1611 - 1619, XP055740331 | |
| OPPOSITION | - Albers John J.; Slee April; O'Brien Kevin D.; Robinson Jennifer G.; Kashyap Moti L.; Kwiterovich Peter O.; Xu Ping; Marcovina Santica M., "Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes)", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20130821), vol. 62, no. 17, doi:10.1016/j.jacc.2013.06.051, ISSN 0735-1097, pages 1575 - 1579, XP028754933 | |
| OPPOSITION | - Terry A. Jacobson, "Lipoprotein(a), Cardiovascular Disease, and Contemporary Management", Mayo Clinic Proceedings, Dowden Health Media, Inc, US, US , (20131101), vol. 88, no. 11, doi:10.1016/j.mayocp.2013.09.003, ISSN 0025-6196, pages 1294 - 1311, XP055740338 | |
| OPPOSITION | - Blacklow, S.C., "Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers", Current Opinion in Structural Biology, GB , (20070801), vol. 17, no. 4, doi:10.1016/j.sbi.2007.08.017, ISSN 0959-440X, pages 419 - 426, XP022273653 | |
| OPPOSITION | - Colhoun, H.M. McKeigue, P.M. Smith, G.D., "Problems of reporting genetic associations with complex outcomes", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20030308), vol. 361, no. 9360, doi:10.1016/S0140-6736(03)12715-8, ISSN 0140-6736, pages 865 - 872, XP004783610 | |
| OPPOSITION | - Willeit Peter; Ridker Paul M; Nestel Paul J; Simes John; Tonkin Andrew M; Pedersen Terje R; Schwartz Gregory G; Olsson Anders G; Colhoun Helen M; Kronenberg Florian; Drechsler Christiane; Wanner Christoph; Mora Samia; Lesogor Anastasia; Tsimikas Sotirios, "Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20181004), vol. 392, no. 10155, doi:10.1016/S0140-6736(18)31652-0, ISSN 0140-6736, pages 1311 - 1320, XP085505005 | |
| OPPOSITION | - Swergold, "REGN727/SAR236553,A FULLY HUMAN PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) MONOCLONAL ANTIBODY: EFFECTS ON SAFETY AND LIPID AND LIPOPROTEIN PROFILES WHEN ADMINISTERED SUBCUTANEOUSLY", ACC.11, (20110405), vol. 57, no. 14, doi:10.1016/S0735-1097(11)62023-8, pages 1 - 1, XP055662879 | |
| OPPOSITION | - COHEN J., ET AL., "Low LDL Cholesterol in Individuals of African Descent Resulting from Frequent Nonsense Mutations in PCSK9", Nature Genetics, Nature Publishing Group US, New York, New York, (20050201), vol. 37, no. 2, doi:10.1038/ng1509, ISSN 1061-4036, pages 161 - 165, XP008102949 | |
| OPPOSITION | - Trégouët David-Alexandre, König Inke R, Erdmann Jeanette, Munteanu Alexandru, Braund Peter S, Hall Alistair S, Großhennig Anika, Linsel-Nitschke Patrick, Perret Claire, Desuremain Maylis, Meitinger Thomas, Wright Ben J, Preuss Michael, Balmforth Anthony J, Ball Stephen G, Meisinger Christa, Germain Cécile, Evans Alun, Arveiler Dominique, Luc Gérald, Ruidavets Jean-Bernard, Morrison Caroline, Van Der Harst Pim, Schreiber Stefan, Neureuther Katharina, Schäfer Arne, Bugert Peter, El Mokhtari Nour E, Schrezenmeir Jürgen, Stark Klaus, Rubin Diana, Wichmann H-Erich, Hengstenberg Christian, Ouwehand Willem, Ziegler Andreas, Tiret Laurence, Thompson John R, Cambien Francois, Schunkert Heribert, Samani Nilesh J, "Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease", Nature Genetics, Nature Publishing Group US, New York, New York, (20090301), vol. 41, no. 3, doi:10.1038/ng.314, ISSN 1061-4036, pages 283 - 285, XP093193406 | |
| OPPOSITION | - Lambert Gilles, Thedrez Aurélie, Croyal Mikaël, Ramin-Mangata Stéphane, Couret David, Diotel Nicolas, Nobécourt-Dupuy Estelle, Krempf Michel, Lebail Jean christophe, Poirier Bruno, Blankenstein Jorg, Villard Elise f., Guillot Etienne, "The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies", CLINICAL SCIENCE., BIOCHEMICAL SOCIETY AND THE MEDICAL RESEARCH SOCIETY, LONDON,, GB, GB , (20170201), vol. 131, no. 4, doi:10.1042/CS20160403, ISSN 0143-5221, pages 261 - 268, XP093193423 | |
| OPPOSITION | - Cohen Jonathan C, Boerwinkle Eric, Mosley Thomas H, Hobbs Helen H, " Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease", The new england journal of medicine, (20060323), vol. 354, no. 12, doi:10.1056/NEJMoa054013, pages 1264 - 1272, XP093193429 | |
| OPPOSITION | - Robert Clarke, John F. Peden, Jemma C. Hopewell, Theodosios Kyriakou, Anuj Goel, Simon C. Heath, Sarah Parish, Simona Barlera, Maria Grazia Franzosi, Stephan Rust, Derrick Bennett, Angela Silveira, Anders Malarstig, Fiona R. Green, Mark Lathrop, Bruna Gigante, Karin Leander, Ulf De Faire, Udo Seedorf, Anders Hamsten, Rory Collins, Hugh Watkins, Martin Farrall, "Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease", New England Journal of Medicine, New England Journal of Medicine, (20091224), vol. 361, no. 26, doi:10.1056/NEJMoa0902604, ISSN 00284793, pages 2518 - 2528, XP055023613 | |
| OPPOSITION | - Ladenson Paul W, Jens D Kristensen, E Chester Ridgway, Anders G Olsson, Bo Carlsson, Irwin Klein, John D Baxter, Bo Angelin, "Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia", The New England Journal of medicine, (20100311), vol. 362, no. 10, doi:10.1056/NEJMoa0905633, pages 906 - 916, XP093168275 | |
| OPPOSITION | - Evan A. Stein, Scott Mellis, George D. Yancopoulos, Neil Stahl, Douglas Logan, William B. Smith, Eleanor Lisbon, Maria Gutierrez, Cheryle Webb, Richard Wu, Yunling Du, Therese Kranz, Evelyn Gasparino, Gary D. Swergold, "Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol", New England Journal of Medicine, (20120322), vol. 366, no. 12, doi:10.1056/NEJMoa1105803, ISSN 00284793, pages 1108 - 1118, XP055049842 | |
| OPPOSITION | - Marc S. Sabatine, Robert P. Giugliano, Anthony C. Keech, Narimon Honarpour, Stephen D. Wiviott, Sabina A. Murphy, Julia F. Kuder, Huei Wang, Thomas Liu, Scott M. Wasserman, Peter S. Sever, Terje R. Pedersen, "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease", The New England journal of medicine, Massachusetts Medical Society, US, US , (20170504), vol. 376, no. 18, doi:10.1056/NEJMoa1615664, ISSN 0028-4793, pages 1713 - 1722, XP055474155 | |
| OPPOSITION | - Schwartz Gregory G., Steg P. Gabriel, Szarek Michael, Bhatt Deepak L., Bittner Vera A., Diaz Rafael, Edelberg Jay M., Goodman Shaun G., Hanotin Corinne, Harrington Robert A., Jukema J. Wouter, Lecorps Guillaume, Mahaffey Kenneth W., Moryusef Angèle, Pordy Robert, Quintero Kirby, Roe Matthew T., Sasiela William J., Tamby Jean-François, Tricoci Pierluigi, White Harvey D., Zeiher Andreas M., "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome", The New England journal of medicine, Massachusetts Medical Society, US, US , (20181129), vol. 379, no. 22, doi:10.1056/NEJMoa1801174, ISSN 0028-4793, pages 2097 - 2107, XP093080663 | |
| OPPOSITION | - Joyce C. Y. Chan, Derek E. Piper, Qiong Cao, Dongming Liu, Chadwick King, Wei Wang, Jie Tang, Qiang Liu, Jared Higbee, Zhen Xia, Yongmei Di, Susan Shetterly, Ziva Arimura, Heather Salomonis, William G. Romanow, Stephen T. Thibault, Richard Zhang, Ping Cao, Xiao-Ping Yang, Timothy Yu, Mei Lu, Marc W. Retter, Gayle Kwon, Kirk Henne, Oscar Pan, Mei-Mei Tsai, Bryna Fuchslocher, Evelyn Yang, Lei Zhou, Ki Jeong Lee, Mark Daris, Jackie Sheng, Yan Wang, Wenyan D. Shene, Wen-Chen Yeh, Maurice Emery, Nigel P. C. Walker, Bei Shan, Margrit Schwarz and Simon M. Jackson, "A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.", Proceedings of the National Academy of Sciences, (20090616), vol. 106, no. 24, doi:10.1073/PNAS.0903849106, ISSN 0027-8424, pages 9820 - 9825, XP002657619 | |
| OPPOSITION | - Utermann G, Hoppichler F, Dieplinger H, Seed M, Thompson G, Boerwinkle E, "Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis.", Proceedings of the National Academy of Sciences, (19890601), vol. 86, no. 11, doi:10.1073/pnas.86.11.4171, ISSN 0027-8424, pages 4171 - 4174, XP093168265 | |
| OPPOSITION | - Romagnuolo Rocco, Scipione Corey A., Boffa Michael B., Marcovina Santica M., Seidah Nabil G., Koschinsky Marlys L., "Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20150501), vol. 290, no. 18, doi:10.1074/jbc.M114.611988, ISSN 0021-9258, pages 11649 - 11662, XP093193435 | |
| OPPOSITION | - Szarek Michael, Bittner Vera A, Aylward Philip, Baccara-Dinet Marie, Bhatt Deepak L, Diaz Rafael, Fras Zlatko, Goodman Shaun G, Halvorsen Sigrun, Harrington Robert A, Jukema J Wouter, Moriarty Patrick M, Pordy Robert, Ray Kausik K, Sinnaeve Peter, Tsimikas Sotirios, Vogel Robert, White Harvey D, Zahger Doron, Zeiher Andreas M, Steg Ph Gabriel, Schwartz Gregory G, "Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial", European Heart Journal, Oxford University Press, GB, GB , (20201121), vol. 41, no. 44, doi:10.1093/eurheartj/ehaa649, ISSN 0195-668X, pages 4245 - 4255, XP093193413 | |
| OPPOSITION | - Frank L J Visseren, "2021 ESC Guidelines on cardiovascular disease prevention in clinical practice", European Heart Journal, GB , (20210907), vol. 42, no. 34, doi:10.1093/eurheartj/ehab484, ISSN 0195-668X, pages 3227 - 3337, XP093168284 | |
| OPPOSITION | - Børge G. Nordestgaard, M. John Chapman, Kausik Ray, Jan Borén, Felicita Andreotti, Gerald F. Watts, Henry Ginsberg, Pierre Amarenco, Alberico Catapano, Olivier S. Descamps, Edward Fisher, Petri T. Kovanen, Jan Albert Kuivenhoven, Philippe Lesnik, Luis Masana, Zeljko Reiner, Marja-Riitta Taskinen, Lale Tokgözoglu, and Anne Tybjærg-Hansen, "Lipoprotein(a) as a cardiovascular risk factor: current status", European Heart Journal, GB , (20101201), vol. 31, no. 23, doi:10.1093/EURHEARTJ/EHQ386, ISSN 0195-668X, pages 2844 - 2853, XP002688211 | |
| OPPOSITION | - Hobbs Helen, White Ann, "Lipoprotein (a) : Intrigues and Insights", CURRENT OPINION IN LIPIDOLOGY, Lippincott Williams and Wilkins, LONDON, GB, LONDON, GB , (19990601), vol. 10, no. 3, doi:10.1097/00041433-199906000-00005, ISSN 0957-9672, pages 225 - 236, XP009557781 | |
| OPPOSITION | - Valmore Bermúdez , Arráiz Nailet, Aparicio Daniel, Rojas Edward, Gotera Daniela, Guerra Xavier, Canelón Roger, Faría Judith, Sorell Luis, Amell Anilsa, Reyna Nadia, Cabrera Mayela, Mengual Edgardo, Cano Raquel, Cano Clímaco, Velasco Manuel, "Lipoprotein(a): From Molecules to Therapeutics", American Journal of Therapeutics, US , (20100501), vol. 17, no. 3, doi:10.1097/MJT.0b013e3181e00bf1, ISSN 1075-2765, pages 263 - 273, XP093168194 | |
| OPPOSITION | - Lamon Fava Stefania, Diffenderfer Margaret, Marcovina Santica, "Lipoprotein(a) metabolism", CURRENT OPINION IN LIPIDOLOGY, Wolters Kluwer Lippincott Williams & Wilkins, USA, USA , (20140601), vol. 25, no. 3, doi:10.1097/MOL.0000000000000070, ISSN 1473-6535, pages 189 - 193, XP009557783 | |
| OPPOSITION | - Angelin, Rudling Mats, "Lipid lowering with thyroid hormone and thyromimetics", CURRENT OPINION IN LIPIDOLOGY, Lippincott Williams and Wilkins, LONDON, GB, LONDON, GB , (20101201), vol. 21, no. 6, doi:10.1097/MOL.0b013e3283402e9c, ISSN 0957-9672, pages 499 - 506, XP009560087 | |
| OPPOSITION | - Kolski Brian, Tsimikas Sotirios, "Emerging therapeutic agents to lower lipoprotein (a) levels", CURRENT OPINION IN LIPIDOLOGY, Lippincott Williams and Wilkins, LONDON, GB, LONDON, GB , (20121201), vol. 23, no. 6, doi:10.1097/MOL.0b013e3283598d81, ISSN 0957-9672, pages 560 - 568, XP009557780 | |
| OPPOSITION | - Lippi G., Targher G., "Optimal therapy for reduction of lipoprotein(a)", JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS., BLACKWELL SCIENTIFIC PUBLICATION, OXFORD., GB, GB , (20120201), vol. 37, no. 1, doi:10.1111/j.1365-2710.2011.01244.x, ISSN 0269-4727, pages 1 - 3, XP093193399 | |
| OPPOSITION | - S Van Wissen, Smilde T J, Trip M D, De Boo Th, Kastelein J J P, Stalenhoef A F H, "Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia", Heart, (20030101), vol. 89, doi:10.1136/heart.89.8.893, pages 893 - 896, XP055393647 | |
| OPPOSITION | - Kraft H. G., Lingenhel A., Raal F. J., Hohenegger M., Utermann G, "Lipoprotein(a) in Homozygous Familial Hypercholesterolemia", Translational Sciences, (20240529), vol. 20, no. 2, doi:10.1161/01.ATV.20.2.522, ISSN 1079-5642, pages 522 - 528, XP093168269 | |
| OPPOSITION | - Sotirios Tsimikas, Joseph L Witztum, Elizabeth R Miller, William J Sasiela, Michael Szarek, Anders G Olsson, Gregory G Schwartz, "High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial", Circulation, American Heart Association, US , (20040914), vol. 110, no. 11, doi:10.1161/01.CIR.0000141728.23033.B5, ISSN 0009-7322, pages 1406 - 1412, XP009560086 | |
| OPPOSITION | - Kamstrup Pia R., Benn Marianne, Tybjærg-Hansen Anne, Nordestgaard Børge G., "Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population : The Copenhagen City Heart Study", Circulation, American Heart Association, US, US , (20080115), vol. 117, no. 2, doi:10.1161/CIRCULATIONAHA.107.715698, ISSN 0009-7322, pages 176 - 184, XP093193441 | |
| OPPOSITION | - O’donoghue Michelle L., Fazio Sergio, Giugliano Robert P., Stroes Erik S.G., Kanevsky Estella, Gouni-Berthold Ioanna, Im Kyungah, Lira Pineda Armando, Wasserman Scott M., Češka Richard, Ezhov Marat V., Jukema J. Wouter, Jensen Henrik K., Tokgözoğlu S. Lale, Mach François, Huber Kurt, Sever Peter S., Keech Anthony C., Pedersen Terje R., Sabatine Marc S., "Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk : Insights From the FOURIER Trial", Circulation, American Heart Association, US, US , (20190319), vol. 139, no. 12, doi:10.1161/CIRCULATIONAHA.118.037184, ISSN 0009-7322, pages 1483 - 1492, XP055886393 | |
| OPPOSITION | - Erik Stroes, Guyton John R., Lepor Norman, Civeira Fernando, Gaudet Daniel, Watts Gerald F., Baccara‐dinet Marie T., Lecorps Guillaume, Manvelian Garen, Farnier Michel, "Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study", Journal of the American Heart Association, John Wiley & Sons, (20160829), vol. 5, no. 9, doi:10.1161/JAHA.116.003421, ISSN 2047-9980, pages 1 - 11, XP055656150 | |
| OPPOSITION | - Krempler F, Kostner G M, Roscher A, Haslauer F, Bolzano K, Sandhofer F, "Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man.", Journal of Clinical Investigation, (19830501), vol. 71, no. 5, doi:10.1172/JCI110896, ISSN 0021-9738, pages 1431 - 1441, XP093168203 | |
| OPPOSITION | - Hofmann S L, Eaton D L, Brown M S, Mcconathy W J, Goldstein J L, Hammer R E, "Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice.", Journal of Clinical Investigation, (19900501), vol. 85, no. 5, doi:10.1172/JCI114602, ISSN 0021-9738, pages 1542 - 1547, XP093168217 | |
| OPPOSITION | - Soutar A K, Mccarthy S N, Seed M, Knight B L, "Relationship between apolipoprotein(a) phenotype, lipoprotein(a) concentration in plasma, and low density lipoprotein receptor function in a large kindred with familial hypercholesterolemia due to the pro664----leu mutation in the LDL receptor gene.", Journal of Clinical Investigation, (19910801), vol. 88, no. 2, doi:10.1172/JCI115329, ISSN 0021-9738, pages 483 - 492, XP093259822 | |
| OPPOSITION | - D J Rader, W A Mann, W Cain, H G Kraft, D Usher, L A Zech, J M Hoeg, J Davignon, P Lupien, M Grossman, "The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans.", Journal of Clinical Investigation, (19950301), vol. 95, no. 3, doi:10.1172/JCI117794, ISSN 00219738, pages 1403 - 1408, XP055215915 | |
| OPPOSITION | - Ober Carole, Nord Alex S., Thompson Emma E., Pan Lin, Tan Zheng, Cusanovich Darren, Sun Ying, Nicolae Raluca, Edelstein Celina, Schneider Daniel H., Billstrand Christine, Pfaffinger Ditta, Phillips Natasha, Anderson Rebecca L., Philips Binu, Rajagopalan Ramakrishnan, Hatsukami Thomas S., Rieder Mark J., Heagerty Patrick J., Nickerson Deborah A., Abney Mark, Marcovina Santica, Jarvik Gail P., Scanu Angelo M., Nicolae Dan L., "Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q", JOURNAL OF LIPID RESEARCH, American Society for Biochemistry and Molecular Biology, Inc., US, US , (20090501), vol. 50, no. 5, doi:10.1194/jlr.M800515-JLR200, ISSN 0022-2275, pages 798 - 806, XP093193431 | |
| OPPOSITION | - Konrad Schmidt, Asma Noureen, Florian Kronenberg, Gerd Utermann, "Structure, function, and genetics of lipoprotein (a)", JOURNAL OF LIPID RESEARCH, American Society for Biochemistry and Molecular Biology, Inc., US, US , (20160801), vol. 57, no. 8, doi:10.1194/jlr.R067314, ISSN 0022-2275, pages 1339 - 1359, XP055502476 | |
| OPPOSITION | - Hiroki Ikenaga , Masaharu Ishihara, Ichiro Inoue, Takuji Kawagoe, Yuji Shimatani, Fumiharu Miura, Yasuharu Nakama, Kazuoki Dai, Takayuki Otani, Kentaro Ejiri, Nozomu Oda, Masayuki Nakamura, Takashi Miki, "Usefulness of Lipoprotein (a) for Predicting Progression of Non-Culprit Coronary Lesions After Acute Myocardial Infarction", Circulation Journal, JP , (20110101), vol. 75, no. 12, doi:10.1253/circj.CJ-11-0365, ISSN 1346-9843, pages 2847 - 2852, XP055522737 | |
| OPPOSITION | - Parhofer Klaus G, "Lipoprotein(a): Medical Treatment Options for an Elusive Molecule", Current Pharmaceutical Design, NL , (20110301), vol. 17, no. 9, doi:10.2174/138161211795428777, ISSN 1381-6128, pages 871 - 876, XP002688212 | |
| OPPOSITION | - Ioanna Gouni-Berthold, Heiner K. Berthold, "Lipoprotein(a): Current Perspectives", Current vascular pharmacology, NL , (20111101), vol. 9, no. 6, doi:10.2174/157016111797484071, ISSN 1570-1611, pages 682 - 692, XP055497835 | |
| OTHER | - "Cholesterol Management Guide for Healthcare Practitioners", American Heart Association - AHA, (20180000), pages 1 - 27, URL: https://www.heart.org/-/media/files/health-topics/cholesterol/cholesterol-guide-for-hc-practitioners-english.pdf?la=en, XP055662885 | - |
| OTHER | - Dubé J B et al, "Lipoprotein(a): more interesting than ever after 50 years", Current Opinion Lipidology, (20120401), vol. 23, no. 2, pages 133 - 140, XP055264229 | - |
| OTHER | - STORM C., "Bringt die 2. Testgeneration den Durchbruch für Lp(a)?", Diagnostik im Dialog, (20130800), vol. 41, pages 11 - 12, XP055575872 | - |
| OTHER | - DANIK, "Lipoprotein(a), Measured With an Assay Independent of Apolipoprotein(a) Isoform Size, and Risk of Future Cardiovascular Events Among Initially Healthy Women", JAMA, (20060920), vol. 296, no. 11, pages 1363 - 1370, XP002609986 | |
| OTHER | - "CHALLENGES IN LIPOPROTEIN (a) MEASUREMENT", Christie Ballantyne, Clinical Lipidology. A Companion to Braunwald's Heart Disease, Saunder Elsevier, (20090000), pages 136 - 143, XP055743471 | |
| OTHER | - KOSCHINSKY M.L. , BOFFA M.B., "Lipoprotein(a): An Important Cardiovascular Risk Factor and a Clinical Conundrum", Endocrinol Metab Clin N Am, (20141126), vol. 43, no. 4, doi:10.1016/j.ecl.2014.08.002, pages 949 - 962, XP055407332 | |
| OTHER | - VAN WISSEN et al, "Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia", Heart, (20030101), vol. 89, pages 893 - 896, XP055393647 | |
| OTHER | - ENKHMAA B. et al, "Lipoprotein (a): impact by ethnicity and environmental and medical conditions", J Lipid Res., (20160701), vol. 57, no. 7, pages 1111 - 25, XP055497837 | |
| OTHER | - IKENAGA H. et al, "Usefulness of Lipoprotein (a) for Predicting Progression of Non-Culprit Coronary Lesions After Acute Myocardial Infarction", Circulation Journal, (20110913), vol. 75, no. 12, pages 2847 - 2852, XP055540050 | |
| OTHER | - WARNICK et al., "Standardization of Measurements for Cholesterol, Triglycerides, and Major Lipoporteins", Lab Med, (20080000), vol. 39, no. 8, doi:10.1309/6UL9RHJH1JFFU4PY, page 481,490, XP055139701 | |
| OTHER | - MARCOVINA et al., "Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions", Clinical Chemistry, (20030000), vol. 49, no. 11, doi:10.1373/clinchem.2003.023689, pages 1785 - 1796, XP055620577 | |
| OTHER | - PARHOFER K, "Lipoprotein(a): Medical Treatment Options for an Elusive Molecule", Current Pharmaceutical Design, (20110301), vol. 17, no. 9, pages 871 - 876, XP002688212 | |
| OTHER | - GOUNI-BERTHOLD I et al, "Lipoprotein(a): Current Perspective", Current Vascular Pharmacology, (20111101), vol. 9, no. 6, pages 682 - 692, XP055497835 | |
| SEARCH | - NORDESTGAARD BORGE G ET AL, "Lipoprotein(a) as a cardiovascular risk factor: current status", EUROPEAN HEART JOURNAL, (201012), vol. 31, no. 23, ISSN 0195-668X, page 2844, XP002688211 [A] 1-15 * abstract * | |
| SEARCH | - PARHOFER KLAUS G, "Lipoprotein(a): Medical Treatment Options for an Elusive Molecule", CURRENT PHARMACEUTICAL DESIGN, (201103), vol. 17, no. 9, ISSN 1381-6128, pages 871 - 876, XP002688212 [Y] 1-15 * table 3 * | |
